SELLAS Life Sciences Group, Inc. SLS
17.95 USD -1.20 (-6.27%)
Regular-session close
17.98 +0.03 +0.17%
After hours · Nov 18, 7:59 PM ET
17.22 Day range 21.40
1.39 52-week range 24.89
- YTD
- +376.13%
- 1 year
- +1,028.93%
Benzinga news
benzinga.com Stock Market Today: Dow Jones, S&P 500, Nasdaq 100 Futures Trade Mixed Ahead of FOMC Minutes— NVDA, AAOI, PANW in Focus (UPDATED) U.S. stocks rose on Wednesday, as the Dow Jones, S&P 500, and Nasdaq 100 index futures advanced, following Tuesday's lower close.
benzinga.com Dolby Laboratories, Jumia Technologies, Applied Optoelectronics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session Dolby slid on below-estimate FY27 guidance, while Red Cat, Jumia, BGIN and other stocks declined in premarket trading.
benzinga.com Why Pony AI Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket Pony AI rose 10.6% after beating Q3 loss estimates but missing sales; Autozi led gainers, while IRIDEX fell 17.6% on results and guidance.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers SELLAS Life Sciences Gr (NASDAQ:SLS) shares rose 169.8% to $20.16 during Tuesday's regular session. The market value of their outstanding shares is at $1.5 billion. As per the press release,…
benzinga.com S&P 500 Down 1%; Disney Posts Upbeat Earnings U.S. stocks fell over 1%; Disney beat estimates, while SLS and GP surged. Oil, gold and silver rose as global markets mostly declined.
benzinga.com Amer Sports, Sellas Life Sciences, Similarweb And Other Big Stocks Moving Higher On Tuesday U.S. stocks fell, but Amer Sports surged on strong results and raised guidance; Sellas jumped 165%, while several other stocks posted gains.
benzinga.com Dow Falls Over 200 Points; US Retail Sales Rise 0.2% In October U.S. stocks were mixed as the Dow fell 200+ points; retail sales rose 0.2%, oil gained 1.5%, and SLS surged 177%.
benzinga.com SELLAS Stock Triples on Cancer Vaccine Cutting Death Risk by 41% in Pivotal Leukemia Trial, SELLAS Life Sciences reports positive Phase 3 REGAL results as galinpepimut-S cuts death risk by 41% in acute myeloid leukemia patients.benzinga.com SELLAS Life Sciences Announces Topline Results From Its Phase 3 REGAL Trial Evaluating Galinpepimut-S In Patients With Acute Myeloid Leukemia Met Primary Endpoint REGAL trial met its primary endpoint with GPS demonstrating statistically significant and clinically meaningful reduction in risk of death by 41% with median overall survival of 24.0 months versus…
benzinga.com SELLAS Life Sciences Gr Q3 EPS $(0.05), Inline SELLAS Life Sciences Gr (NASDAQ:SLS) reported quarterly losses of $(0.05) per share which met the analyst consensus estimate. This is a 16.67 percent increase over losses of $(0.06) per share from…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers SELLAS Life Sciences Gr (NASDAQ:SLS) stock rose 19.6% to $9.6 during Friday's pre-market session. The market value of their outstanding shares is at $1.6 billion. As per the news, the Q3…benzinga.com SELLAS Life Sciences To Present Data From Completed Phase 2 Study Of SLS009 For Treatment Of R/R AML, At 68th ASH Annual Meeting And Exposition − Company to present Phase 2 clinical data evaluating SLS009 (tambiciclib) in combination with azacitidine and venetoclax in patients who have previously failed venetoclax-based therapy − − Patients…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Pulmonx (NASDAQ:LUNG) stock increased by 33.1% to $2.63 during Wednesday's regular session. The company's market cap stands at $85.0 million. As per the press release, Q3 earnings came out…
benzinga.com SELLAS Life Sciences Stock Stumbles: What's Going On? SELLAS Life Sciences Group shares are falling Wednesday as the company's Phase 3 leukemia study moves toward its final analysis.benzinga.com SELLAS Life Sciences Announces Its Pivotal Phase 3 Study Of Galinpepimut-S In Acute Myeloid Leukemia Participants Surpasses Pre-Specified 80th Event SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS’’ or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer
